**MINUTES**

**CPIC CONFERENCE CALL**

DATE: May 2, 2019

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Mary will send the poll link.  |
| Response to FDA letter to Inova | FDA issued a warning letter in early April 2019 to the pharmacogenomics testing lab, Inova. They specifically mentioned concerns with *CYP2C19* testing to guide escitalopram and sertraline therapy. CPIC is aware of this letter and issued a response on the PharmGKB blog: <https://pharmgkb.blogspot.com/2019/04/cyp2c19-testing-may-assist-with.html>.  | None. |
| Conflicts of Interest for CPIC guideline authors | In recent years, CPIC has been criticized for having too many guideline authors with conflicts of interest (COI). There’s a COI form that every prospective author must fill out, which is reviewed by the CPIC Steering Committee. In addition to listing conflicts, authors must explain how each relationship could and/or will not influence the guideline development process or specific recommendations. If you have no conflicts, you still need to fill out and submit the form.  | Prospective authors to return COI forms. |
| CPIC meeting  | The open CPIC meeting will be held June 6th and 7th at St. Jude Children’s Research Hospital in Memphis, TN. The preliminary program and registration is available at <https://cpicpgx.org/meetings/>. We have 200+ pre-registrants to date.  | If you are not staying at the Peabody Hotel or a hotel recommended by CPIC staff, please check with Dawn Bowen (dawn.bowen@stjude.org) or April Blackenship (april.blackenship@stjude.org) about the hotel. |
| Term standardization part 2 | Keito Hoshitsuki, the PGY2 Clinical Pharmacogenomics Resident at St. Jude Children’s Research Hospital, presented “Allele Function and Phenotype Terms Standardization Part II.” The aim of this project is to extend CPIC’s previous term standardization project (PMID 27441996) to non-drug metabolizing enzymes, non-transporters, and non-HLA genes. A unique challenge is the heterogeneity among the PD genes and how they affect drug response. Questions were asked as to whether we could expand to include somatic variants; concern around phenotype terms that are drug-specific (e.g., aminoglycoside ototoxicity susceptible); the need to differentiate between biochemical and clinical allele function; and harmonizing with ClinVar’s existing terms for genes that have both PGx and disease implications. Slides will be posted to the CPIC website with the minutes.  | More to come on this project. |
| The International Society of Psychiatric Genetics (ISPG) guidelines on the use of genetic testing in psychiatry | Daniel Mueller, MD, PhD and Chad Bousman, MPH, PhD described the ISPG Pharmacogenetic Testing Statement. ISPG is focused on promoting education in psychiatric genetics, both for the scientific community and for the lay public. One of ISPG’s four domains is “pharmacogenetic tests to guide optimal treatment.” Key discussion points among members of the writing committee for the statement included 1) perceptions of the evidence; 2) perspectives on the evidence required; 3) clinical perspectives on pharmacogenomic testing; 4) clinical validity vs clinical utility. The statement can be found here: <https://ispg.net/genetic-testing-statement/>.Slides will be posted to the CPIC website with the minutes. | If you have questions/comments, please contact Daniel Mueller (daniel.mueller@camh.ca) and Chad Bousman (chad.bousman@ucalgary.ca)  |